Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients

Creative Commons License

Damci T. , YALIN S., Balci H. , Osar Z., KORUGAN Ü., ÖZYAZAR M. , ...Daha Fazla

DIABETES CARE, cilt.27, ss.1077-1080, 2004 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 27 Konu: 5
  • Basım Tarihi: 2004
  • Doi Numarası: 10.2337/diacare.27.5.1077
  • Dergi Adı: DIABETES CARE
  • Sayfa Sayıları: ss.1077-1080


OBJECTIVE - Orlistat leads to improved glycemic control in obese type 2 diabetic patients, which is attributed to decreased insulin resistance associated with weight loss. Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are gut hormones that are secreted in response to food intake, and they both stimulate insulin secretion. Orlistat decreases fat absorption and increases intestinal fat content, which may lead to increased secretion of these peptides. In this pilot study, we tested the hypothesis that increased levels of these intestinal hormones may be involved in the improvement of postprandial hyperglycemia observed previously with orlistat in type 2 diabetic patients.